New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
07:05 EDTISISIsis Pharmaceuticals initiates Phase 1 study of ISIS-ANGPTL3 Rx
Isis Pharmaceuticals nannounced that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3 Rx, an antisense drug targeting angiopoietin-like 3 protein, an independent risk factor for cardiovascular disease. ISIS-ANGPTL3 Rx is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3 Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity. Isis plans to evaluate ISIS-ANGPTL3 Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
10:02 EDTISISIsis Pharmaceuticals reports Q1 EPS (14c), consensus (20c)
Subscribe for More Information
May 4, 2015
11:04 EDTISISIsis Pharmaceuticals partnership deal generally expected, says Piper Jaffray
Piper Jaffray noted that Isis Pharmaceuticals (ISIS) had been indicating a high level of interest in its FXIrx anti-clotting antisense program ahead of announcing its deal with Bayer (BAYRY) and the firm believes the announcement of a partnership pact was generally expected. The firm said it already included "meaningful" economics from the FXI program in its valuation for Isis and maintains a Neutral rating on the stock, which is up 4.6% to $60.92 in morning trading.
09:03 EDTISISIsis Pharmaceuticals enters into license agreement with Bayer HealthCare
Subscribe for More Information
April 30, 2015
16:54 EDTISISIsis Pharmaceuticals earns $10M milestone payment from Biogen
Subscribe for More Information
April 24, 2015
09:32 EDTISISJPMorgan Smid biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 22, 2015
16:25 EDTISISIsis Pharmaceuticals reports positive data from ISIS-TTR Rx
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use